DOAC–Stop reverses the anticoagulant effect of asundexian and milvexian
Journal of Thrombosis and Haemostasis · 2025-09 · 23 (9) · 2830-2836
DOI: 10.1016/j.jtha.2025.05.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-09. Verfasst von Ella K Fitzpatrick und 2 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Atherosclerosis Research Institute and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical …. Hauptthemen laut MEDLINE: Blood Coagulation, Anticoagulants, Factor Xa Inhibitors, Charcoal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research.
Abstract (Originalsprache)
BACKGROUND: Asundexian and milvexian are small-molecule factor (F)XIa inhibitors, whereas abelacimab is an antibody that binds FXI and blocks its activation and activity. All 3 FXI inhibitors are currently undergoing phase 3 evaluation. Similar to heparin and dabigatran, asundexian, milvexian, and abelacimab prolong the activated partial thromboplastin time (APTT) in a concentration-dependent manner. DOAC-Stop (DS) is an activated charcoal-based compound that adsorbs direct oral anticoagulants such as dabigatran, but not heparin, from plasma. It is unknown whether DS also neutralizes asundexian and milvexian. OBJECTIVE: This study aimed to determine whether DS reverses the prolongation of the APTT caused by asundexian or milvexian. Dabigatran was used as a positive control, while abelacimab and heparin served as negative controls. METHODS: The APTT in human plasma, with or without asundexian, milvexian, abelacimab, dabigatran, or heparin, was determined before and after DS treatment. RESULTS: As expected, all drugs produced concentration-dependent prolongation of the APTT. DS returned the APTT to baseline values with asundexian, milvexian, and dabigatran, but not with abelacimab or heparin. The APTT was prolonged in a more than additive manner with the combination of 2.5 μM milvexian and 0.125 U/mL heparin. However, DS reversed only the APTT prolongation induced by milvexian, but not that by heparin. CONCLUSION: DS reverses the effect of asundexian and milvexian on the APTT and distinguishes between the APTT effects of milvexian and heparin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thrombosis and Atherosclerosis Research Institute and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
- Thrombosis and Atherosclerosis Research Institute and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Thrombosis and Atherosclerosis Research Institute and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada; Department o…
Förderung
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research
Zitieren
APA
Fitzpatrick, E. K., Fredenburgh, J. C., & Weitz, J. I. (2025). DOAC–Stop reverses the anticoagulant effect of asundexian and milvexian. Journal of Thrombosis and Haemostasis, 23(9), 2830-2836. https://doi.org/10.1016/j.jtha.2025.05.032
Vancouver
Fitzpatrick EK, Fredenburgh JC, Weitz JI. DOAC–Stop reverses the anticoagulant effect of asundexian and milvexian. Journal of Thrombosis and Haemostasis. 2025;23(9):2830-2836. doi:10.1016/j.jtha.2025.05.032
BibTeX
@article{Fitzpatrick2025,
author = {Fitzpatrick, Ella K and Fredenburgh, James C and Weitz, Jeffrey I},
title = {DOAC–Stop reverses the anticoagulant effect of asundexian and milvexian},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {9},
pages = {2830--2836},
doi = {10.1016/j.jtha.2025.05.032}
}
EUVIMED